Association between recent use of proton pump inhibitors and nontyphoid salmonellosis: A nested case-control study

Clinical Infectious Diseases

Volumn 59, Issue 11, 2014, Pages 1554-1558

  Wu, Hau Hsin ^a   Chen, Yung Tai ^b,c   Shih, Chia Jen ^b,d   Lee, Yi Tzu ^b,d   Kuo, Shu Chen ^d,e   Chen, Te Li ^d,f  

^a CENTER FOR DISEASE CONTROL   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c TAIPEI CITY HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^f CHENG HSIN GENERAL HOSPITAL   (Taiwan)

Author keywords

Nontyphoid salmonellosis; Proton pump inhibitors; Risks

Indexed keywords

ANTIBIOTIC AGENT; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; STEROID;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG WITHDRAWAL; FEMALE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONTYPHOID SALMONELLOSIS; PRIORITY JOURNAL; SALMONELLOSIS; STEROID THERAPY; TAIWAN; AGED; CASE CONTROL STUDY; CHEMICALLY INDUCED; ODDS RATIO; SALMONELLA INFECTIONS;

ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PROTON PUMP INHIBITORS; SALMONELLA INFECTIONS; TAIWAN;

EID: 84924361604     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu628     Document Type: Article

References (23)

1. Hohmann EL Nontyphoidal salmonellosis. Clin Infect Dis 2001; 32: 263-9.
2. Majowicz SE, Musto J, Scallan E, et al. The global burden of nontyphoidal Salmonella gastroenteritis. Clin Infect Dis 2010; 50: 882-9.
3. Public Health Agency of Canada. Salmonella enterica spp, 2011. Available at: http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/salmonellaent-eng.php. Accessed 18 November 2013.
4. Lee SC, Yang PH, Shieh WB, Lasserre R. Bacteremia due to non-typhi Salmonella: analysis of 64 cases and review. Clin Infect Dis 1994; 19: 693-6.
5. Shimoni Z, Pitlik S, Leibovici L, et al. Nontyphoid Salmonella bacteremia: age-related differences in clinical presentation, bacteriology, and outcome. Clin Infect Dis 1999; 28: 822-7.
6. Kunz LJ, Waddell WR. Association of Salmonella enteritis with operations on the stomach. N Engl J Med 1956; 255: 555-9.
7. Morpeth SC, Ramadhani HO, Crump JA. Invasive non-typhi Salmonella disease in Africa. Clin Infect Dis 2009; 49: 606-11.
8. Gordon MA Salmonella infections in immunocompromised adults. J Infect 2008; 56: 413-22.
9. Doorduyn Y, Van Den Brandhof WE, Van Duynhoven YT, Wannet WJ, Van Pelt W. Risk factors for Salmonella Enteritidis and Typhimurium (DT104 and non-DT104) infections in the Netherlands: predominant roles for raw eggs in Enteritidis and sandboxes in Typhimurium infections. Epidemiol Infect 2006; 134: 617-26.
10. Garcia Rodriguez LA, Ruigomez A, Panes J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol 2007; 5: 1418-23.
11. Doorduyn Y, Van Pelt W, Siezen CL, et al. Novel insight in the association between salmonellosis or campylobacteriosis and chronic illness, and the role of host genetics in susceptibility to these diseases. Epidemiol Infect 2008; 136: 1225-34.
12. Fried M, Siegrist H, Frei R, et al. Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. Gut 1994; 35: 23-6.
13. Mullin JM, Valenzano MC, Whitby M, et al. Esomeprazole induces upper gastrointestinal tract transmucosal permeability increase. Aliment Pharmacol Ther 2008; 28: 1317-25.
14. Zedtwitz-Liebenstein K, Wenisch C, Patruta S, Parschalk B, Daxbock F, Graninger W. Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med 2002; 30: 1118-22.
15. Brophy S, Jones KH, Rahman MA, et al. Incidence of Campylobacter and Salmonella infections following first prescription for PPI: a cohort study using routine data. Am J Gastroenterol 2013; 108: 1094-100.
16. Fujita T. Risk factors of community-acquired enteric infection. Am J Gastroenterol 2014; 109: 137-8.
17. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613-9.
18. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83.
19. Dhar JM, al-Khader AA, al-Sulaiman M, al-Hasani MK. Non-typhoid Salmonella in renal transplant recipients: a report of twenty cases and review of the literature. Q J Med 1991; 78: 235-50.
20. Etminan M, Forooghian F, Brophy JM, Bird ST, Maberley D. Oral fluoroquinolones and the risk of retinal detachment. JAMA 2012; 307: 1414-9.
21. Reimer C. Safety of long-term PPI therapy. Best Pract Res Clin Gastroenterol 2013; 27: 443-54.
22. Garcia Rodriguez LA, Ruigomez A. Gastric acid, acid-suppressing drugs, and bacterial gastroenteritis: how much of a risk? Epidemiology 1997; 8: 571-4.
23. Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther 2011; 34: 1269-81.